Parallel evolution and differences in seroprevalence of SARS-CoV-2 antibody between patients with cancer and health care workers in a tertiary cancer centre during the first and second wave of COVID-19 pandemic: canSEROcov-II cross-sectional study.
Fiche publication
Date publication
février 2022
Journal
European journal of cancer (Oxford, England : 1990)
Auteurs
Membres identifiés du Cancéropôle Est :
Dr ARNOULD Laurent, Dr BERTAUT Aurélie, Dr COUDERT Bruno, Pr COUTANT Charles, Pr GHIRINGHELLI François, Dr LADOIRE Sylvain, Mme PARNALLAND Sophie, Mme TRUNTZER Caroline, Dr VINCENT Julie, Dr HERVIEU Alice, Dr FAVIER Laure, Dr BENGRINE-LEFEVRE Leila, Dr DESMOULINS Isabelle, Dr FUMET Jean-David, Dr HENNEQUIN Audrey, Dr ZANETTA Sylvie, Dr MAYEUR Didier
Tous les auteurs :
Ladoire S, Rederstorff E, Goussot V, Parnalland S, Briot N, Ballot E, Truntzer C, Ayati S, Bengrine-Lefevre L, Bremaud N, Coudert B, Desmoulins I, Favier L, Fraisse C, Fumet JD, Hennequin A, Hervieu A, Ilie S, Kaderbhai C, Lagrange A, Martin N, Mazilu I, Mayeur D, Palmier R, Simonet-Lamm AL, Vincent J, Zanetta S, Arnould L, Coutant C, Bertaut A, Ghiringhelli F
Lien Pubmed
Résumé
Patients with cancer are a population at high risk of severe infection from SARS-CoV-2. Patients with cancer regularly attend specialised healthcare centres for management and treatment, where they are in contact with healthcare workers (HCWs). Numerous recommendations target both patients with cancer and HCWs to minimise the spread of SARS-CoV-2 during these interactions.
Mots clés
Antibody, COVID-19, Cancer center, Cancer patients, Cross sectional study, Health care workers, SARS-CoV-2, Serology, Seroprevalence
Référence
Eur J Cancer. 2022 Feb 1;165:13-24